Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lilly reports positive gastric cancer trial data

Lilly reports positive gastric cancer trial data

19th October 2012

Lilly has reported positive clinical trial data supporting the safety and efficacy of the multipurpose compound ramucirumab in the treatment of metastatic gastric cancer.

During the recent phase III trial Regard, the compound was shown to deliver overall survival benefits and prolong progression-free survival among patients, thus meeting its primary endpoint goal.

In this study, the drug was combined with best supportive care and assessed as a second-line treatment in patients with metastatic gastric and gastroesophageal junction cancers, compared to placebo.

Regard is one of two phase III studies evaluating ramucirumab as a gastric cancer therapy, with the second, Rainbow, having completed patient enrolment last month.

Dr Richard Gaynor, vice-president for product development and medical affairs for Lilly Oncology, said the data "reinforces our confidence in the ramucirumab development programme, in which we currently have six phase III studies ongoing in five tumour types – breast, colorectal, gastric, hepatocellular and lung cancer".

This comes in the same week that Lilly received US regulatory approval for a new indication of Alimta, its therapy for lung cancer.ADNFCR-8000103-ID-801472532-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.